EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Benitec Biopharma's enterprise value is $3.25 Mil.
Benitec Biopharma's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $0.06 Mil. Therefore, Benitec Biopharma's EV-to-Revenue for today is 53.30.
The historical rank and industry rank for Benitec Biopharma's EV-to-Revenue or its related term are showing as below:
BNTC'
s EV-to-Revenue Range Over the Past 10 Years
Min: -47683.85 Med: 145.07 Max: 4272.9
Current: 53.3
During the past 11 years, the highest EV-to-Revenue of Benitec Biopharma was 4272.90. The lowest was -47683.85. And the median was 145.07.
BNTC's EV-to-Revenue is ranked worse than 77.9% of 1036
companies
in the Biotechnology industry
Industry Median: 7.98
vs BNTC: 53.30
The historical data trend for Benitec Biopharma's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Benitec Biopharma's EV-to-Revenue
For the Biotechnology subindustry, Benitec Biopharma's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Benitec Biopharma's EV-to-Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Benitec Biopharma's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Benitec Biopharma's EV-to-Revenue falls into.
Benitec Biopharma's current Enterprise Value is $3.25 Mil.
Benitec Biopharma's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.06 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Benitec Biopharma's share price for today is $8.95.
Benitec Biopharma's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.04.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Benitec Biopharma EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of Benitec Biopharma's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Benitec Biopharma (Benitec Biopharma) Business Description
Benitec Biopharma Inc is a biotechnology company developing a proprietary therapeutic technology platform that combines RNA interference with gene therapy for providing sustained, long-lasting silencing of disease-causing genes from a single administration. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The company is developing product candidates in chronic and life-threatening human disease areas including Orphan disease: Oculopharyngeal Muscular Dystrophy (OPMD) and Infectious disease: Hepatitis B Virus (HBV). BB-301 is currently under development by the group; it is designed to slow, or halt, the disease progression.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
BNTC has been successfully added to your 